{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:16:22Z","timestamp":1793686582974,"version":"4.5.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.annonc.2026.04.017","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T12:32:00Z","timestamp":1780230720000},"page":"1133-1143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-3416","authenticated-orcid":false,"given":"S.","family":"Kopetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-2030","authenticated-orcid":false,"given":"H.S.","family":"Wasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.S.","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Usari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Beyzarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Whalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-6324","authenticated-orcid":false,"given":"E.","family":"Elez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.annonc.2026.04.017_bib1","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2026.04.017_bib2","first-page":"1","article-title":"The evolving treatment landscape in BRAF-V600E\u2013mutated metastatic colorectal cancer","volume":"42","author":"Tabernero","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"18","key":"10.1016\/j.annonc.2026.04.017_bib3","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","article-title":"Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma","volume":"23","author":"Delord","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8_Suppl","key":"10.1016\/j.annonc.2026.04.017_bib4","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1158\/1538-7445.AM2012-3790","article-title":"Abstract 3790: Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor","volume":"72","author":"Stuart","year":"2012","journal-title":"Cancer Res"},{"issue":"34","key":"10.1016\/j.annonc.2026.04.017_bib5","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer","volume":"33","author":"Corcoran","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7387","key":"10.1016\/j.annonc.2026.04.017_bib6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.017_bib7","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.017_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov"},{"issue":"24","key":"10.1016\/j.annonc.2026.04.017_bib9","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N Engl J Med"},{"issue":"4_suppl","key":"10.1016\/j.annonc.2026.04.017_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.119","article-title":"BREAKWATER safety lead-in (SLI): encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC)","volume":"41","author":"Kopetz","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.017_bib11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.04.017_bib12","doi-asserted-by":"crossref","first-page":"S435","DOI":"10.1016\/j.annonc.2024.08.584","article-title":"515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): Updated results from the BREAKWATER safety lead-in (SLI)","volume":"35","author":"Tabernero","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.017_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2026.04.017_bib17","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. V1.2026. 2026."},{"key":"10.1016\/j.annonc.2026.04.017_bib18","article-title":"PII-046 - An evaluation of the drug interaction potential of encorafenib in combination with binimetinib using the inje cocktail in patients with BRAF V600-mutant unresectable or metastatic melanoma or other advanced solid tumors","author":"Piscitelli","year":"2024","journal-title":"Presented at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting 2024; Colorado Springs, CO, USA; March 27-29, 2024"},{"issue":"10","key":"10.1016\/j.annonc.2026.04.017_bib19","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","article-title":"Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics","volume":"57","author":"de Man","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.017_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.04.017_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fon-2022-1249","article-title":"SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H\/dMMR BRAFV600E-mutant mCRC","volume":"20","author":"Elez","year":"2024","journal-title":"Future Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:59:55Z","timestamp":1785283195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426001791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0923753426001791"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.017","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}